Puntis Stephen, Minichino Amedeo, De Crescenzo Franco, Cipriani Andrea, Lennox Belinda, Harrison Rachael
Department of Psychiatry, University of Oxford, Oxford, UK.
Oxford University Medical School, Medical Sciences Divisional Office, Oxford, UK.
Cochrane Database Syst Rev. 2020 Nov 2;11(11):CD013287. doi: 10.1002/14651858.CD013287.pub2.
Psychosis is an illness characterised by the presence of hallucinations and delusions that can cause distress or a marked change in an individual's behaviour (e.g. social withdrawal, flat or blunted effect). A first episode of psychosis (FEP) is the first time someone experiences these symptoms that can occur at any age, but the condition is most common in late adolescence and early adulthood. This review is concerned with FEP and the early stages of a psychosis, referred to throughout this review as 'recent-onset psychosis.' Specialised early intervention (SEI) teams are community mental health teams that specifically treat people who are experiencing, or have experienced, a recent-onset psychosis. SEI teams provide a range of treatments including medication, psychotherapy, psychoeducation, educational and employment support, augmented by assertive contact with the service user and small caseloads. Treatment is time limited, usually offered for two to three years, after which service users are either discharged to primary care or transferred to a standard adult community mental health team. Evidence suggests that once SEI treatment ends, improvements may not be sustained, bringing uncertainty about the optimal duration of SEI to ensure the best long-term outcomes. Extending SEI has been proposed as a way of providing continued intensive treatment and continuity of care, of usually up to five years, in order to a) sustain the positive initial outcomes of SEI; and b) improve the long-term trajectory of the illness.
To compare extended SEI teams with treatment as usual (TAU) for people with recent-onset psychosis. To compare extended SEI teams with standard SEI teams followed by TAU (standard SEI + TAU) for people with recent-onset psychosis.
On 3 October 2018 and 22 October 2019, we searched Cochrane Schizophrenia's study-based register of trials, including registries of clinical trials.
We selected all randomised controlled trials (RCTs) comparing extended SEI with TAU for people with recent-onset psychosis and all RCTs comparing extended SEI with standard SEI + TAU for people with recent-onset psychosis. We entered trials meeting these criteria and reporting usable data as included studies.
We independently inspected citations, selected studies, extracted data and appraised study quality. For binary outcomes we calculated the risk ratios (RRs) and their 95% confidence intervals (CIs). For continuous outcomes we calculated the mean difference (MD) and their 95% CIs, or if assessment measures differed for the same construct, we calculated the standardised mean difference (SMD) with 95% CIs. We assessed risk of bias for included studies and created a 'Summary of findings' table using the GRADE approach.
We included three RCTs, with a total 780 participants, aged 16 to 35 years. All participants met the criteria for schizophrenia spectrum disorders or affective psychoses. No trials compared extended SEI with TAU. All three trials randomly allocated people approximately two years into standard SEI to either extended SEI or standard SEI + TAU. The certainty of evidence for outcomes varied from low to very low. Our primary outcomes were recovery and disengagement from mental health services. No trials reported on recovery, and we used remission as a proxy. Three trials reported on remission, with the point estimate suggesting a 13% increase in remission in favour of extended SEI, but this included wide confidence intervals (CIs) and a very uncertain estimate of no benefit (RR 1.13, 95% CI 0.97 to 1.31; 3 trials, 780 participants; very low-certainty evidence). Two trials provided data on disengagement from services with evidence that extended SEI care may result in fewer disengagements from mental health treatment (15%) in comparison to standard SEI + TAU (34%) (RR 0.45, 95% CI 0.27 to 0.75; 2 trials, 380 participants; low-certainty evidence). There may be no evidence of a difference in rates of psychiatric hospital admission (RR 1.55, 95% CI 0.68 to 3.52; 1 trial, 160 participants; low-certainty evidence), or the number of days spent in a psychiatric hospital (MD -2.70, 95% CI -8.30 to 2.90; 1 trial, 400 participants; low-certainty evidence). One trial found uncertain evidence regarding lower global psychotic symptoms in extended SEI in comparison to standard SEI + TAU (MD -1.90, 95% CI -3.28 to -0.52; 1 trial, 156 participants; very low-certainty evidence). It was uncertain whether the use of extended SEI over standard SEI + TAU resulted in fewer deaths due to all-cause mortality, as so few deaths were recorded in trials (RR 0.38, 95% CI 0.09 to 1.64; 3 trials, 780 participants; low-certainty evidence). Very uncertain evidence suggests that using extended SEI instead of standard SEI + TAU may not improve global functioning (SMD 0.23, 95% CI -0.29 to 0.76; 2 trials, 560 participants; very low-certainty evidence). There was low risk of bias in all three trials for random sequence generation, allocation concealment and other biases. All three trials had high risk of bias for blinding of participants and personnel due to the nature of the intervention. For the risk of bias for blinding of outcome assessments and incomplete outcome data there was at least one trial with high or unclear risk of bias.
AUTHORS' CONCLUSIONS: There may be preliminary evidence of benefit from extending SEI team care for treating people experiencing psychosis, with fewer people disengaging from mental health services. Evidence regarding other outcomes was uncertain. The certainty of evidence for the measured outcomes was low or very low. Further, suitably powered studies that use a consistent approach to outcome selection are needed, but with only one further ongoing trial, there is unlikely to be any definitive conclusion for the effectiveness of extended SEI for at least the next few years.
精神病是一种以幻觉和妄想为特征的疾病,这些症状会给患者带来痛苦,或导致其行为发生显著变化(例如社交退缩、情感平淡或迟钝)。首次发作精神病(FEP)是指某人首次出现这些症状,可发生于任何年龄,但在青春期后期和成年早期最为常见。本综述关注首次发作精神病及精神病的早期阶段,在本综述中统称为“近期发病精神病”。专门的早期干预(SEI)团队是社区心理健康团队,专门治疗正在经历或曾经经历过近期发病精神病的患者。SEI团队提供一系列治疗,包括药物治疗、心理治疗、心理教育、教育和就业支持,并通过与服务使用者的积极接触和少量病例负荷加以强化。治疗有时间限制,通常为两到三年,之后服务使用者要么出院转至初级保健机构,要么转至标准的成人社区心理健康团队。有证据表明,一旦SEI治疗结束,改善效果可能无法持续,这使得确定SEI的最佳持续时间以确保最佳长期结果变得不确定。有人提议延长SEI,作为提供持续强化治疗和连续护理的一种方式,通常长达五年,目的是:a)维持SEI最初的积极效果;b)改善疾病的长期发展轨迹。
比较近期发病精神病患者接受延长SEI团队治疗与常规治疗(TAU)的效果。比较近期发病精神病患者接受延长SEI团队治疗与标准SEI团队治疗后再接受TAU(标准SEI + TAU)的效果。
2018年10月3日和2019年10月22日,我们检索了Cochrane精神分裂症基于研究的试验注册库,包括临床试验注册库。
我们选择了所有比较近期发病精神病患者接受延长SEI与TAU的随机对照试验(RCT),以及所有比较近期发病精神病患者接受延长SEI与标准SEI + TAU的随机对照试验。我们将符合这些标准并报告可用数据的试验作为纳入研究。
我们独立检查文献、选择研究、提取数据并评估研究质量。对于二元结局,我们计算风险比(RRs)及其95%置信区间(CIs)。对于连续结局,我们计算平均差(MD)及其95% CIs,或者如果同一结构的评估指标不同,我们计算标准化平均差(SMD)及其95% CIs。我们评估纳入研究的偏倚风险,并使用GRADE方法创建“结果总结”表。
我们纳入了三项RCT,共有780名参与者,年龄在16至